First human test of exosome drug begins – no cure yet, just safety check
NCT ID NCT07219940
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug called SOB100 in 15 healthy volunteers to see if it is safe and how the body processes it. SOB100 is a tiny particle (exosome) designed to target a specific protein (HLA-G). The study does not aim to treat any disease; it only checks for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Parexel International - Baltimore Early Phase Clinical Unit
RECRUITINGBaltimore, Maryland, 21225, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.